Recent Advancements in the Atopic Dermatitis Mechanism
Open accessThe DOI matches its Crossref record; 159 of the 159 references it cites were found in a registry or an index.
Abstract
Atopic dermatitis (AD) is a recurrent, chronic, inflammatory, itchy skin disorder that affects up to 20% of the pediatric population and 10% of the adult population worldwide. Onset typically occurs early in life, and although cardinal disease features are similar across all ages, different age groups and ethnicities present distinct clinical characteristics. The disease imposes a significant burden in all health-related quality of life domains, both in children and adults, and a substantial economic cost both at individual and national levels. The pathophysiology of AD includes a complex and multifaceted interplay between the impaired dysfunctional epidermal barrier, genetic predisposition, and environmental contributors, such as chemical and/or biological pollutants and allergens, in the context of dysregulated TH2 and TH17 skewed immune response. Regarding the genetic component, the loss of function mutations encoding structural proteins such as filaggrin, a fundamental epidermal protein, and the more recently identified variations in the epidermal differentiation complex are well-established determinants resulting in an impaired skin barrier in AD. More recently, epigenetic factors have facilitated AD development, including the dysbiotic skin microbiome and the effect of the external exposome, combined with dietary disorders. Notably, the interleukin (IL)-31 network, comprising several cell types, including macrophages, basophils, and the generated cytokines involved in the pathogenesis of itch in AD, has recently been explored. Unraveling the specific AD endotypes, highlighting the implicated molecular pathogenetic mechanisms of clinically relevant AD phenotypes, has emerged as a crucial step toward targeted therapies for personalized treatment in AD patients. This review aims to present state-of-the-art knowledge regarding the multifactorial and interactive pathophysiological mechanisms in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Tobacco smoke, whether through active or passive exposure, delivers benzene to the skin, which interferes with the inhibitory ability of TREG cells to secrete IL-10 and exert anti-inflammatory effects, which results in a higher prevalence of AD in children with relatives who smoke.”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The number of M2 macrophages expressing IL-31, CD68+ macrophages, and basophils in biopsies of skin affected by AD is positively related to TSLP and periostin expression in the epidermis of affected skin in patients with AD and also to disease severity.61”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Thus, IL-4 and IL-13 constitute the main cytokines associated with the pathogenesis of early AD, as in addition to promoting type 2 inflammatory responses and recruiting eosinophils to the skin, they damage the epidermal barrier by suppressing the expression of structural proteins such as filaggrin, loricrin, and lipids, while concomitantly increasing collagen deposition in the dermis, which”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“IL-18 acts on receptors (IL-18Rα) overexpressed on eosinophils in patients with AD and the histamine released by mast cells and basophils increases the expression of IL-18 on eosinophils by binding histamine with H2R and H4R, suggesting a relevant function of IL-18 and histamine in eosinophilic inflammation in AD.61”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [61]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Elevated serum levels of IL-21 are observed in patients with AD, primarily produced by Th17 cells, which is associated with greater AD severity when compared to healthy controls so IL-21 directly promotes type 2 inflammation and suppresses Th1 responses by suppressing INFγ production.61”
From Update on the pathogenesis of atopic dermatitis. (2024) · cites this paper as [61]
Experimental — accuracy not yet measured
17 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Wild, C. P. (2005) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-05-0456 · Cited by 2,562 · cited 1×
“[108], highlighting the bidirectional interaction of the external environment and human health and disease, complementing the gene—environmental associations in the pathogenesis of allergic diseases.”
BackgroundTwo Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110 · cited 1×
“Subsequently, new therapeutic targets aiming at inhibiting IL-4R using monoclonal antibodies and JAK inhibitors are developed [137,138], while the inhibition of IL-13 using monoclonal antibodies attenuates the itch in AD [18,19].”
BackgroundLangan, S. M., Irvine, A. D., & Weidinger, S. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31286-1 · Cited by 1,852
Weidinger, S., Beck, L. A., Bieber, T., Kabashima, K., & Irvine, A. D. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0001-z · Cited by 1,549
Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch
Oetjen, L. K., Mack, M. R., Feng, J., Whelan, T. M., Niu, H., Guo, C. J., Chen, S., Trier, A. M., Xu, A. Z., Tripathi, S. V., et al. (2017) · Cell · doi:10.1016/j.cell.2017.08.006 · Cited by 1,092 · cited 3×
“…IL-4, IL-13, and IL-31, act through the TRP channel ankyrin transmembrane protein 1 (TRPA1) and the transient receptor potential (TRP) channel vallinoid 1 (TRPV1) by activating the calcium influx in the sensory fibers [134], while TSLP acts directly on the sensory nerves by binding to its receptor.”
BackgroundAkdis, C. A. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00538-7 · Cited by 981 · cited 1×
“Microbiome dysbiosis in AD impairs immune responses and, in response to the ex-posome effects, contributes to the “leaking epithelium”, the subepithelial translocation of dysbiotic microbiota and opportunistic pathogens [82].”
BackgroundStänder, S. (2021) · New England Journal of Medicine · doi:10.1056/nejmra2023911 · Cited by 756
Guttman-Yassky, E., Bissonnette, R., Ungar, B., Suárez-Fariñas, M., Ardeleanu, M., Esaki, H., Suprun, M., Estrada, Y., Xu, H., Peng, X., et al. (2019) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.08.022 · Cited by 697 · cited 1×
“Importantly, the data indicate a restorative effect of dupilumab in AD by progressively ameliorating systemic and cutaneous abnormalities [63].”
BackgroundWollenberg, A., Blauvelt, A., Guttman‐Yassky, E., Worm, M., Lynde, C., Lacour, J. ‐., Spelman, L., Katoh, N., Saeki, H., Poulin, Y., et al. (2021) · British Journal of Dermatology · doi:10.1111/bjd.19574 · Cited by 638 · cited 2×
“Subsequently, new therapeutic targets aiming at inhibiting IL-4R using monoclonal antibodies and JAK inhibitors are developed [137,138], while the inhibition of IL-13 using monoclonal antibodies attenuates the itch in AD [18,19].”
BackgroundMethodPathophysiology of atopic dermatitis: Clinical implications
Kim, J., Kim, B. E., & Leung, D. Y. M. (2019) · Allergy and Asthma Proceedings · doi:10.2500/aap.2019.40.4202 · Cited by 635 · cited 2×
“Furthermore, FLG and LOR, involucrin, and keratins 1,10 are downregulated in the presence of T2 inflammation cytokines, such as IL-4, IL-13, IL-22, and IL-31, in a process mediated by OVO-like 1 (OVOL1), an upstream transcription factor for these proteins [49,57].”
Background
Cited by
Update on the pathogenesis of atopic dermatitis.
Criado, P. R., Miot, H. A., Bueno-Filho, R., Ianhez, M., Criado, R. F. J., & de Castro, C. C. S. (2024) · Anais brasileiros de dermatologia · doi:10.1016/j.abd.2024.06.001 · Cited by 66
Interleukin-4 and Atopic Dermatitis: Why Does it Matter? A Narrative Review
Torres, T. R., Mendes‐Bastos, P., Cruz, M. J., Duarte, B., Filipe, P., Lopes, M. J. P., & Gonçalo, M. (2025) · Dermatology and Therapy · doi:10.1007/s13555-025-01352-y · Cited by 46
“This lipid deficiency further exacerbates barrier dysfunction and facil‑ itates the chronic inflammatory state observed in AD [42, 47].”
Advances in Atopic Dermatitis Treatment: From Pathogenesis to Natural Product‐Based Therapies
Fan, X., Liu, Z., Yang, W., Zhang, H., Zhong, H., Pang, Y., Ye, X., Wu, C., & Li, L. (2025) · Phytotherapy Research · doi:10.1002/ptr.70056 · Cited by 22
“The incidence rate of AD in infants is 11.3%–12.7% and 6.9%–7.6% in adults, respectively (Savva et al. 2024; Weins et al. 2024).”
InfluentialLivshits, G., & Kalinkovich, A. (2024) · Cells · doi:10.3390/cells13221899 · Cited by 16
Lin, Y., Zheng, L., Xu, Y., Wang, X., Li, J., Zheng, L., Liang, G., & Chen, L. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.4c01322 · Cited by 16
Biomarkers in Atopic Dermatitis in Children: A Comprehensive Review
Indolfi, C., Grella, C., Klain, A., Dinardo, G., Colosimo, S., Piatto, D., Nespoli, C., Perrotta, A., & del Giudice, M. M. (2025) · Life · doi:10.3390/life15030375 · Cited by 18
Urzua, I. E., Vidal, M., Solano, M. V., Jaramillo, J. E. B., Donis, G. G. D. L. C., & Valverde, A. R. (2025) · Cureus · doi:10.7759/cureus.86937 · Cited by 14
“When the skin is dysfunctional, it becomes permeable, often feels very dry, has weakened immunity, and allows more irritants and allergens in, which can influence the growth and worsening of chronic dermatological illnesses [11].”
Chatzigeorgiou, I., Koumaki, D., Vakirlis, E., Papadimitriou, I., & Gregoriou, S. (2024) · Medicina · doi:10.3390/medicina60081376 · Cited by 10
“Together with the activation of innate lymphoid 2 cells (ILC2s), TSLP initiates the innate and adaptive immune responses of atopic dermatitis [11].”
BackgroundSelf-citationBeyond the blockade: unmet needs in systemic targeted atopic dermatitis therapy
Zhang, L., Peng, G., Wang, M., Niyonsaba, F., & Gao, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1712757 · Cited by 10
Mun, D., Ryu, S., Choi, H., Kwak, M., Oh, S., & Kim, Y. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01875-z · Cited by 9
“The pathophysiology of AD is complex, involving genetic, environmental, and immunological fac - tors [ 3 ].”
Qin, J., Meng, Z., Min, W., Wang, X., & Zou, Y. (2025) · Clinical Cosmetic and Investigational Dermatology · doi:10.2147/ccid.s574980 · Cited by 9
Luo, Y.-F., Deng, Y., Yang, F., Meiduosiji, Xiong, X., Yuan, Y.-L., & Ao, S.-H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1567817 · Cited by 7
Chen, Y., Gong, Z., Liang, S., Zhang, Y., Cheng, W., Jia, X., Ren, L., & Wang, X. (2025) · Digital Health · doi:10.1177/20552076251377957 · Cited by 7
Recent progress in tyrosine kinase 2 inhibitors for atopic dermatitis
Liu, Q., Xia, Y., Liu, L., Zhou, Y., & Li, Y. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2391825 · Cited by 7
“In particular, JAK inhibitors have shown significant promise in controlling pruritus associated with AD [31].”
Lee, J., Choi, H., Shin, H. S., & Kim, G.-D. (2024) · Molecules · doi:10.3390/molecules29245951 · Cited by 9
“Genetic mutations, such as those in the filaggrin gene, contribute to skin barrier dysfunction, whereas immune dysregulation is marked by an imbalance in Th2 and Th1 cytokines, promoting immunoglobulin (Ig) E-mediated hypersensitivity [20,21].”
The neuro-immune insights of itch: peripheral mechanisms and central glial contributions
Li, Z., Yu, N., Feng, S., Wang, X., Chu, Y.-X., & Liu, X. (2026) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-025-00834-3 · Cited by 5
Exploring the Association Between Atopic Dermatitis and Malignancy
Drum, D. L., Wan, L., Jallorina, A. G., & Lee-Wong, M. F. (2024) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2026.04.012 · Cited by 5
Peng, R., Huang, X., Bao, Y., Luo, G., Zeng, J., & Tang, L. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1895580 · Cited by 6
Toledo, M. D. G. T., Lazo, R. E. L., Domingos, E. L., Zein, A. K. E., Cobre, A. D. F., Borba, H. H. L., Ferreira, L. M., & Pontarolo, R. (2024) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2024.106275 · Cited by 5
Zhu, X., & Wu, W. (2024) · Skin Research and Technology · doi:10.1111/srt.13858 · Cited by 3
“12,13 Additionally, the JAK/STAT signaling pathway holds significance in the pathogenesis of AD and inflammation.”
BackgroundRetractedKaushal, P., & Awasthi, R. (2025) · Medicine in Novel Technology and Devices · doi:10.1016/j.medntd.2025.100404 · Cited by 3
Tran, N. T., Tran, A. H., & Trinh, D.-T. T. (2025) · Integrative Medicine Research · doi:10.1016/j.imr.2025.101256 · Cited by 3
“18,19 23 AA may alleviate symptoms of AD through a range of potential immunomodulatory mechanisms.”
Qu, H., Xu, R., Lang, J., Li, Z., Lang, J., Li, Y., Wang, J., Li, Y., Ren, J., & Lang, N. (2025) · Dermatitis · doi:10.1177/17103568251380252 · Cited by 3
Skin-Immune-Neuro-Gastro-Endocrine (SINGE) System: Lighting the Fire on Atopic Dermatitis Research
Paz, M., & Lio, P. (2025) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1504a5329 · Cited by 3
Knockdown of S100A9 inhibits pyroptosis and promotes PPAR signaling pathway in atopic dermatitis
Li, L., Yu, M., Zheng, T., & Hu, L. (2025) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2025.152431 · Cited by 2
The role of the Hippo pathway in allergic diseases: Mechanisms and therapeutic potential
Gong, X., Fei, J., & Cui, Y. (2025) · International Immunopharmacology · doi:10.1016/j.intimp.2025.115490 · Cited by 2
Gómez-Farto, A., Jiménez-Escobar, A. L., Pérez-González, N., Lozano-White, A., Expósito-Herrera, J., Montero‐Vílchez, T., Clares, B., & Arias‐Santiago, S. (2025) · Gels · doi:10.3390/gels11110880 · Cited by 2
“The prevalence of AD varies by geographic region, affecting up to 25% of children and 10% of adults [3].”
Zhang, L., Zhou, N., Wu, Z., Chen, X., Zhu, H., Li, S., Han, J., Miao, G., Wu, L., Zhu, R., et al. (2026) · Dermatology and Therapy · doi:10.1007/s13555-026-01655-8 · Cited by 2
“This disease negatively impacts the quality of life (QoL) of patients in physical, psychosocial, and mental functioning, while also imposing significant economic burdens on patients and their families, and is linked to various systemic comorbidities [4, 5].”
Czarnowicki, T., Sugita, K., Yiu, Z. Z. N., Díez-Ribas, S., García‐Jiménez, I., Guttman‐Yassky, E., & Santamaria‐Babí, L. F. (2026) · Allergy · doi:10.1111/all.70347 · Cited by 2
“Polymorphisms in genes regulating Th2 cytokines, such as IL4R and IL13 , further amplify the Th2 axis, driving IgE-mediated sensitization and eosinophil recruitment, hallmarks of AD [162, 163].”
Cumulative Life Course Impairment in Atopic Dermatitis: A Comprehensive Review
Brescia, C., Palagiano, C., Turco, M., Potestio, L., di Vico, F., & Napolitano, M. (2026) · Medical Sciences · doi:10.3390/medsci14040499 · Cited by 2
“Although approximately 85% of cases develop before the age of five and many patients experience partial or complete remission during adolescence, AD may persist into adulthood or arise de novo later in life [2–4].”
Siquier-Dameto, G., Iguaran-Pérez, A., Beltrán, J. G., Bellia, G., Giori, A. M., Boadas‐Vaello, P., & Verdú, E. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051701 · Cited by 2
Nymand, L. K., Nielsen, M., Christensen, M. O., Thomsen, S. F., Thyssen, J. P., & Egeberg, A. (2025) · Acta Dermato Venereologica · doi:10.2340/actadv.v105.43071 · Cited by 1
“In cases of moderate-to-severe AD with frequent or intense flares, levels of these pro-inflammatory cytokines are even further elevated (25).”
Unraveling the Pathogenesis of Asian Atopic Dermatitis: Key Characteristics and Insights
Lee, S. H., Ha, N. G., & Jang, Y. H. (2025) · Annals of Dermatology · doi:10.5021/ad.25.008 · Cited by 1
“Studies on the scalp microbiome show increased diversity of non-Malassezia fungi in AD patients compared to healthy controls 77,81 .”
Epigenetic Modification in Preclinical and Clinical Dermatological Itch Conditions
Fujishiro, A., Vecchio, S. L., Giordano, R., Yosipovitch, G., & Arendt‐Nielsen, L. (2026) · European Journal of Pain · doi:10.1002/ejp.70214 · Cited by 1
“…2024; Khosrojerdi et al. 2024; Livshits and Kalinkovich 2024; Martin et al. 2020; Mu and Zhang 2020; Nedoszytko et al. 2020; Özdemіr and Öksüz 2024; Savva et al. 2024; Schmidt and de Guzman Strong 2021; da Silva Duarte and Sanabani 2024), 2 review articles on psoriasis (Domingo et al. 2020; Timis…”
Innovation in pediatric atopic dermatitis care: examining emerging topical treatment options
McGee, C., Jafari, A. J., & Hebert, A. A. (2026) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2026.2641800 · Cited by 1
Wang, X. L., Jia, N., Joo, H., Wang, S., Zhang, C., Chen, Q., & Jiang, W. (2026) · Journal of Inflammation Research · doi:10.2147/jir.s594212 · Cited by 2
Is Dermoscopy Destroying Clinical Dermatology?
Conforti, C., Ambrosio, L., Giuffrida, R., Longo, C., Pellacani, G., & Zalaudek, I. (2025) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1504a5823 · Cited by 1
ALLERGIC CONTACT DERMATITIS AND ATOPIC DERMATITIS: HIGHLIGHTS OF THE OVERLAP SYNDROME
Konovalenko, L. V., Litus, O., & Litus, V. I. (2024) · Clinical and Preventive Medicine · doi:10.31612/2616-4868.3.2024.01
Sosin, J., Pilarz, A., Stachowiak, J., Zwierzchowska, M., Sojka, A., Salamon, D., & Domagała, W. (2024) · Quality in Sport · doi:10.12775/qs.2024.31.55934
Atopic dermatitis - the review
Wrona, J., Kaźmierczyk, A., Kęsik, J., Madycka, D., Michta, K., Słaboń, M., Wójcik, A., Stępniak, K., Telega, W., & Wnuczek, K. (2025) · Quality in Sport · doi:10.12775/qs.2025.37.56851
“A healthy epidermal barrier serves as protection against physical, chemical, and microbial challenges 7,11 .”
InfluentialToledo, A., Theodoro, M. I. D. B., Cremonezi, I. M., Perin, M. M., Manske, T. D., Crispim, B. D. S., de Oliveira, M. E. D., da Silva, C. G. V., Taques, R. D. V., Oliveira, C. M. D. F., et al. (2025) · International Journal of Health Science · doi:10.22533/at.ed.1595425140110
Trichoscopic clues of the scalp in moderate to severe atopic dermatitis: a monocentric analysis
Starace, M. V. R., Gurioli, C., Orioni, G., Cedirian, S., Brunetti, T., Rapparini, L., & Piraccini, B. M. (2025) · Italian Journal of Dermatology and Venereology · doi:10.23736/s2784-8671.25.08127-7
AD-like facial erythema following secukinumab therapy in a patient with psoriasis: a case report
Jin, N., & Kim, H. S. (2025) · Daehan geonseon hakoeji (Online) · doi:10.23203/jksp.2025.22.1.32
Tsikhan, N., Lialikau, S. A., Belevtsev, M. V., Zverko, U. L., Курбат, М. Н., Kupchinskaya, A. N., Dubovik, V., & Nikolskaya, A. (2025) · Immunopathology Allergology Infectology · doi:10.14427/jipai.2025.1.68
Interpreting palmar hyperlinearity and cytokine signals in infant atopic dermatitis risk
Chen, S., & Chen, C. (2025) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.70162
“Given IL-18's dual role in Th1 and Th2 pathways, its ability to modulate itch, and its impact on barrier integrity, 5–7 the cytokine is strikingly absent from current infant risk panels.”
Dermatitis: an update for primary care nurses
Nazarko, L. (2025) · Practice Nursing · doi:10.12968/pnur.2025.0078
Guyon, M., & Arribas, M. T. V. (2024) · Zaguan (University of Zaragoza Repository)
Terapia actual de la dermatitis atópica
Fernández Fernández, M. (2024) · Communities in ADDI (University of the Basque Country)
Pápulas en los codos y las rodillas como hallazgo clínico en la dermatitis atópica
López, J. V. (2026) · Piel · doi:10.1016/j.piel.2025.07.006
Development and validation of a predictive risk nomogram for atopic dermatitis
Cui, J., Song, Y., & Rui, Q. (2025) · Advances in Dermatology and Allergology · doi:10.5114/ada.2025.158087
“Moreover, AD frequently presents early in life [25], with approximately 60% of patients developing symptoms within the first year of life and about 90% by the age of 5 [26].”
Jęśkowiak, I., Nowotarska, P., Gębarowska, E., Bażanów, B., Gębarowski, T., Szafran, R. G., Chwirot, A., Krzyżak, E., Szeląg, A., Mą̨czyński, M., et al. (2026) · Pharmacological Reports · doi:10.1007/s43440-026-00839-5
“AD stands out as the most common of these disorders [3], establishing a pathological environment where patients are highly susceptible to secondary bacterial, viral, and fungal infections due to impaired barrier integrity, a dysregulated immune response, and trauma from frequent scratching [4].”
Therapeutic effects of fucoidan with different molecular weight on atopic dermatitis
Wang, Z., Lai, Y., Li, Q., Zhang, N., Zheng, B., Yang, H., Huang, Y., Yang, Y., Zhang, X., Ye, J., et al. (2026) · Food Bioscience · doi:10.1016/j.fbio.2026.108706
Piu, A. (2026) · Electronic Theses and Dissertations Repository (University of Pisa)
Smolnikov, E. V., Byazrova, M. G., Litovkina, A. O., Elisyutina, O. G., & Fedenko, E. S. (2026) · Russian Journal of Allergy · doi:10.36691/rja17090
Ning, W., 杭凌宇, Xue, Y., Zha, W., 王闰, Xue, K., Ning, J.-T., Zhao, J., Wang, L., & Yuan, H. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18060661
“Atopic dermatitis (AD), a chronic, relapsing inflammatory skin disease, is characterized pathologically by a vicious cycle where “immune-inflammatory dysregulation” and “skin physical barrier defect” exacerbate each other [18,19].”
The effectiveness of baricitinib in the complex therapy of chronic eczema
Дащук, А. А. (2026) · Ukrainian Journal of Dermatology Venerology Cosmetology · doi:10.30978/ujdvk2026-2-21
“…[5, 13, 24], які є досить ефек-тивними за легких форм екземи, але у разі більш поширених форм вони недостатньо дієві та Н а сьогодні екзема залишається одним із най-поширеніших хронічних запальних реци-дивних захворювань шкіри, що вражає до 20 % дітей та до 10 % дорослих [19].”
Prenatal and perinatal risk factors for atopic dermatitis in offspring - a literature review
Czapla, A., Pawelec, N., Podkościelna, J., Załuska, U., Ryszkowska, K., Krzyżowska, K., Perzyńska, J., Bagińska, W., & Kasterka, N. (2026) · Quality in Sport · doi:10.12775/qs.2026.59.72770
Shared Pathways between Psoriasis and Atopic Dermatitis
Trovato, F., Chello, C., Amato, S., Guardo, A. D., AMORE, E., Bennardo, L., Richetta, A. G., Grieco, T., Nisticò, S. P., Pellacani, G., et al. (2026) · Dermatology Practical & Conceptual · doi:10.5826/dpc.1603a6662
Li, Z., & Li, Y. (2026) · Frontiers in Pediatrics · doi:10.3389/fped.2026.1902799
Tapinarof as a new topical treatment in atopic dermatitis
Galli, E., Cinicola, B. L., Maiello, T., Comberiati, P., Cipriani, F., Andrenacci, B., Gragnoli, B., & Ricci, G. (2025) · Italian Journal of Pediatric Allergy and Immunology · Cited by 1
Minato, K., Chikazawa, M., Unno, K., Yamana, Y., Tagawa, T., Kuwahara, H., & Mizuno, M. (2026) · Nutrients · doi:10.3390/nu18203446
“Morphologically, the lesion of ACD shows erythema and edema at first (acute stage), possibly within 24–72 h, then crust and scales (subacute stage), and ultimately lichenification (chronic stage) [3,6,7].”
Wen, W., Xu, J., Wang, B., Teng, Y., Cai, S., & Yi, X. (2026) · Pediatric Allergy and Immunology · doi:10.1111/pai.70524
“1,22 NF-kappaB and oxidative-stress annotations provide further context, and these programs may complement type 2 inflammation.”
Air Pollution: Clinical Considerations in Urticaria and Atopic Dermatitis
Santamaría-Salazar, L. C. (2026) · Current Treatment Options in Allergy · doi:10.1007/s40521-026-00429-z
Cavaion, J. C. L. (2026) · Literacia Cientifica Editora & Cursos eBooks · doi:10.53524/lit.edt.978-65-84528-72-7/27
Metadata
- Authors
- Savva, M., Papadopoulos, N. G., Gregoriou, S., Katsarou, S., Papapostolou, N., Makris, M., & Xepapadaki, P.
- Affiliations
- National and Kapodistrian University of Athens (GR)
- Department of Dermatology and Venereology, Faculty of Medicine, National and Kapodistrian University of Athens, Andreas Sygros Hospital, 16121 Athens, Greece
- Corresponding author
- Savva, Maria
- ORCID
- Venue
- Frontiers in Bioscience-Landmark
- Publisher
- IMR Press
- Published
- 2024-02-22
- Volume
- 29
- Issue
- 2
- Pages
- 84-84
- ISSN
- 2768-6698 (ISSN-L)
- 2768-6701
- OpenAlex
- W4392106846
- Semantic Scholar
- 4c9790a5cd6a4e9f456e1c65c61b1fe6d8ec96fb
- Cited by
- 53
- References
- 159
- Citations by year
- 2026: 18 · 2025: 26 · 2024: 9
- FWCI
- 4.14
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Frontiers in Bioscience-Landmark (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
- Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
- Keywords
- atopic dermatitis, pathophysiology, skin barrier dysfunction, filaggrin, epidermal differentiation complex, genetic susceptibility, epigenetics, skin microbiome, exposome, dietary factors, IL-31, pruritus, endotypes, pediatric atopic dermatitis, quality of life, economic burden
- MeSH terms
- Adult, Child, Dermatitis, Atopic, Humans, Quality of Life, Skin, Cytokines, Genetic Predisposition to Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.